Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

J&J consumer health care division providing 300 reps to detail Alza's pediatric attention hyperactivity deficit disorder Rx drug Concerta following its anticipated late summer launch in the U.S. Approximately 110 McNeil reps will contact pediatricians exclusively, while the rest will detail to general practitioners and family care physicians. Under the agreement with Alza, McNeil will receive payments for its sales efforts and payments based upon specific sales attained. Alza is hoping to leverage McNeil's sales experience in pediatrics with Children's Tylenol and Children's Motrin. The J&J division co-promotes two other Rx drugs: Daiichi's Floxin otic and Allergan's Ocuflox ophthalmic solution

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts